He points to a November 2026 study he says suggests semaglutide and other GLP-1 drugs may help beyond diabetes and obesity in people with schizophrenia.
Recap by typeshit. Post by Dr Ahmad Rehan Khan on X.
The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
The Partnership for Safe Medicines calls the compounding illegal and risky, as RFK Jr. pitches a state-regulated marketplace for peptides like BPC-157, per RAPS.
A UK guide covers how the three drugs differ, getting jabs or tablets on the NHS versus privately, and what alternatives exist.
Loading…